

METHODS IN MOLECULAR BIOLOGY™

Series Editor
John M. Walker
School of Life Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:
<http://www.springer.com/series/7651>

Antibody Methods and Protocols

Edited by

Gabriele Proetzel

The Jackson Laboratory, Bar Harbor, ME, USA

Hilmar Ebersbach

NIBR Biologics Center, Novartis Institutes for BioMedical Research, Basel, Switzerland

 **Humana Press**

Editors

Gabriele Proetzel
The Jackson Laboratory
Bar Harbor, ME, USA

Hilmar Ebersbach
NIBR Biologics Center
Novartis Institutes for BioMedical Research
Basel, Switzerland

ISSN 1064-3745 ISSN 1940-6029 (electronic)
ISBN 978-1-61779-930-3 ISBN 978-1-61779-931-0 (eBook)
DOI 10.1007/978-1-61779-931-0
Springer New York Dordrecht Heidelberg London

Library of Congress Control Number: 2012938221

© Springer Science+Business Media, LLC 2012

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

Cover illustration: Artwork provided by Michael V. Wiles, PhD.

Printed on acid-free paper

Humana Press is part of Springer Science+Business Media (www.springer.com)

Preface

Antibodies play such a central role in research and development due to their high versatility and universal applicability that research without them would be inconceivable. Their use ranges from protein localization, cell separation, and screening to functional assays being applied in many formats including high-throughput assays. With the breakthrough in the generation of monoclonal antibodies, the practical potential of antibodies due to their almost-designer specificities was immediately recognized, especially regarding their applications in diagnostics and therapeutics. However, surprisingly it still took until the 1990s for antibodies to begin to make a substantial impact in drug development and to be applied as effective therapeutics. The industry has since grown into a multibillion-dollar market, and 34 therapeutic antibodies have been FDA approved, most of them still being on the market in 2012. Additionally, literally hundreds of antibodies are now in the development pipeline. These are being generated by a variety of platforms incorporating many technical enhancements, such as improved half-life and effector functions. This rapidly growing field is the result of many advancing technologies allowing current developments to take advantage of molecular engineering to create tailor-made antibodies. New antibody formats and scaffolds are being explored, exemplified by bispecifics and antibody drug conjugates.

This volume, *Antibody Methods and Protocols*, attempts to provide insight into the generation of antibodies using in vitro and in vivo approaches, as well as technical aspects for screening, analysis, and modification of antibodies and antibody fragments. Even though this volume covers subjects as diverse as classical methods, such as hybridoma technology and phage display, to the more recent developments including Fc engineering, it is still beyond the scope of any single volume to present the multitude of techniques now available for antibody isolation, screening, and modification. Instead, we have focused on basic protocols for isolating antibodies and, at the same time, selected a range of specific areas with the aim of providing guides for the overall process of antibody isolation and characterization as well as protocols for enhancing classical antibodies and antibody fragments. The antibody process begins with antigen generation and presentation; this is discussed in the first chapter. An overview of in vitro approaches is presented in the chapters by Ron Geyer, Dev Sidhu, Konstantin Petropoulos, Christoph Rader, Georg Thom, and Elisabetta Traggiai. These cover phage display, ribosome display, as well the use of human B cells for antibody isolation. Chapters by E-Chiang Lee, Michel Cogné, and Chonghui Zhang discuss the usefulness of mice in the development of antibodies, in particular genetically engineered mice to develop human and humanized antibodies directly in the mouse. We touch upon biophysical and biochemical characterization, affinity measurements by surface plasmon resonance, and glycosylation analysis with chapters by Michael Schröml and Christiane Jäger. Further, we have included a description of antibody fragments, cloning approaches, and modification by pegylation presented in chapters by Christoph Rader and Simona Jevšvar. More recent developments in the field of antibody engineering addressing half-life extension, effector function modulation, and the rising field of bispecific antibodies, as well as approaches for antibody decoration including antibody drug conjugates, are covered in

chapters by Ulrich Brinkmann, Gloria Meng, and Michel Cogné. While we cannot address all the new and exciting developments in this fast-developing field, we believe that this volume provides a broad and useful background to support ongoing efforts and encourages the development of new imaginative approaches.

The assembly of this volume would not have happened without the commitment of all contributors, their discussions and rapid responses, making this a valuable and relevant contribution to antibody methods and protocols. We are also grateful to Dr. Michael V. Wiles for his help in editing of this volume and providing many dinners.

We like to thank Dr. John Walker for the opportunity to assemble this work and his encouragement and help throughout the process. We wish to thank also the team from Humana Press, especially David Casey, for continuous support.

We hope that this volume will provide useful insights for both experts and novices and that it will stimulate further development of antibody approaches and encourage the community to continuously share ideas and protocols.

Bar Harbor, ME, USA
Basel, Switzerland

Gabriele Proetzel
Hilmar Ebersbach

Contents

| | |
|--|-----------|
| <i>Preface</i> | <i>v</i> |
| <i>Contributors</i> | <i>ix</i> |
| 1 Antigen Presentation for the Generation of Binding Molecules <i>Hilmar Ebersbach, Gabriele Proetzel, and Chonghui Zhang</i> | 1 |
| 2 Recombinant Antibodies and In Vitro Selection Technologies <i>C. Ronald Geyer, John McCafferty, Stefan Dübel, Andrew R.M. Bradbury, and Sachdev S. Sidhu</i> | 11 |
| 3 Phage Display <i>Konstantin Petropoulos</i> | 33 |
| 4 Generation of Human Fab Libraries for Phage Display <i>Christoph Rader</i> | 53 |
| 5 Selection of Human Fab Libraries by Phage Display <i>Christoph Rader</i> | 81 |
| 6 Ribosome Display <i>George Thom and Maria Groves</i> | 101 |
| 7 Hybridoma Technology for the Generation of Monoclonal Antibodies <i>Chonghui Zhang</i> | 117 |
| 8 The Application of Transgenic Mice for Therapeutic Antibody Discovery <i>E-Chiang Lee and Michael Owen</i> | 137 |
| 9 Production of Human or Humanized Antibodies in Mice <i>Brice Laffleur, Virginie Pascal, Christophe Sirac, and Michel Cogné</i> | 149 |
| 10 Immortalization of Human B Cells: Analysis of B Cell Repertoire and Production of Human Monoclonal Antibodies <i>Elisabetta Traggiai</i> | 161 |
| 11 Kinetic Screening in the Antibody Development Process <i>Michael Schräml and Matthias Biehl</i> | 171 |
| 12 Temperature-Dependent Antibody Kinetics as a Tool in Antibody Lead Selection <i>Michael Schräml and Leopold von Proff</i> | 183 |
| 13 Determination of Antibody Glycosylation by Mass Spectrometry <i>Christiane Jäger, Claudia Ferrara, Pablo Umaña, Anne Zeck, Jörg Thomas Regula, and Hans Koll</i> | 195 |
| 14 Cloning, Expression, and Purification of Monoclonal Antibodies in scFv-Fc Format <i>Jiahui Yang and Christoph Rader</i> | 209 |

| | | |
|----|--|------------|
| 15 | PEGylation of Antibody Fragments for Half-Life Extension | 233 |
| | <i>Simona Jevševar, Mateja Kusterle, and Maja Kenig</i> | |
| 16 | Bispecific Antibody Derivatives Based on Full-Length IgG Formats | 247 |
| | <i>Michael Grote, Alexander K. Haas, Christian Klein, Wolfgang Schaefer, and Ulrich Brinkmann</i> | |
| 17 | Generation of Fluorescent IgG Fusion Proteins in Mammalian Cells | 265 |
| | <i>Alexander K. Haas, Klaus Mayer, and Ulrich Brinkmann</i> | |
| 18 | Methods to Engineer and Identify IgG ₁ Variants with Improved FcRn Binding or Effector Function | 277 |
| | <i>Robert F. Kelley and Y. Gloria Meng</i> | |
| 19 | Class-Specific Effector Functions of Therapeutic Antibodies | 295 |
| | <i>Virginie Pascal, Brice Laffleur, and Michel Cogné</i> | |
| | <i>Erratum</i> | <i>E1</i> |
| | <i>Index</i> | <i>319</i> |

Contributors

- MATTHIAS BIEHL • *Roche Diagnostics GmbH, Penzberg, Germany*
- ANDREW R.M. BRADBURY • *Los Alamos National Laboratory, Los Alamos, NM, USA*
- ULRICH BRINKMANN • *Large Molecule Research, Roche Pharma Research and Early Development, Penzberg, Germany*
- MICHEL COGNÉ • *CNRS UMR6101, Contrôle des Réponses Immunes B et Lymphoproliférations, Université de Limoges, Limoges, France*
- STEFAN DÜBEL • *Technische Universität Braunschweig, Braunschweig, Germany*
- HILMAR EBERSBACH • *NIBR Biologics Center, Novartis Institutes for BioMedical Research, Basel, Switzerland*
- CLAUDIA FERRARA • *pRED, Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland*
- C. RONALD GEYER • *University of Saskatchewan, Saskatoon, SK, Canada*
- MICHAEL GROTE • *Large Molecule Research, Roche Pharma Research and Early Development, Penzberg, Germany*
- MARIA GROVES • *MedImmune Ltd, Cambridge, UK*
- ALEXANDER K. HAAS • *Large Molecule Research, Roche Pharma Research and Early Development, Penzberg, Germany*
- CHRISTIANE JÄGER • *pRED, Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland*
- SIMONA JEVŠEVAR • *Sandoz Biopharmaceuticals, Mengeš, Lek Pharmaceuticals d.d, Mengeš, Slovenia*
- ROBERT F. KELLEY • *Antibody Engineering, Genentech Inc, South San Francisco, CA, USA*
- MAJA KENIG • *Sandoz Biopharmaceuticals, Mengeš, Lek Pharmaceuticals d.d, Mengeš, Slovenia*
- CHRISTIAN KLEIN • *Large Molecule Research, Roche Pharma Research and Early Development, Schlieren, Switzerland*
- HANS KOLL • *pRED, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany*
- MATEJA KUSTERLE • *Sandoz Biopharmaceuticals, Mengeš, Lek Pharmaceuticals d.d, Mengeš, Slovenia*
- BRICE LAFFLEUR • *CNRS UMR6101, Contrôle des Réponses Immunes B et Lymphoproliférations, Université de Limoges, Limoges, France*
- E-CHIANG LEE • *Kymab Ltd, Meditrina, Cambridge, UK*
- KLAUS MAYER • *Large Molecule Research, Roche Pharma Research and Early Development, Penzberg, Germany*
- JOHN MCCAFFERTY • *University of Cambridge, Cambridge, UK*

- Y. GLORIA MENG • *Biochemical and Cellular Pharmacology, Genentech Inc, South San Francisco, CA, USA*
- MICHAEL OWEN • *Kymab Ltd, Meditrina, Cambridge, UK*
- VIRGINIE PASCAL • *CNRS UMR6101, Contrôle des Réponses Immunes B et Lymphoproliférations, Université de Limoges, Limoges, France*
- KONSTANTIN PETROPOULOS • *MorphoSys AG, Martinsried/Planegg, Germany*
- GABRIELE PROETZEL • *The Jackson Laboratory, Bar Harbor, ME, USA*
- LEOPOLD VON PROFF • *Roche Diagnostics GmbH, Penzberg, Germany*
- CHRISTOPH RADER • *Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Cancer Biology and Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida Jupiter, FL, USA*
- JÖRG THOMAS REGULA • *pRED, Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany*
- WOLFGANG SCHAEFER • *Large Molecule Research, Roche Pharma Research and Early Development, Penzberg, Germany*
- MICHAEL SCHRÄML • *Roche Diagnostics GmbH, Penzberg, Germany*
- SACHDEV S. SIDHU • *University of Toronto, Toronto, ON, Canada*
- CHRISTOPHE SIRAC • *CNRS UMR6101, Contrôle des Réponses Immunes B et Lymphoproliférations, Université de Limoges, Limoges, France*
- GEORGE THOM • *MedImmune Ltd, Cambridge, UK*
- ELISABETTA TRAGGIAI • *Translational Science, Novartis Institute for Biomedical Research, Basel, Switzerland*
- PABLO UMAÑA • *pRED, Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland*
- JIAHUI YANG • *Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA*
- ANNE ZECK • *NMI, Naturwissenschaftliches und Medizinisches Institut, Universität Tübingen, Reutlingen, Germany*
- CHONGHUI ZHANG • *NIBR Biologics Center, Novartis Institutes for BioMedical Research, Cambridge, MA, Switzerland*